Skip to main content

Our roundup of Canadian small-caps in the news today.

iStockPho

Our roundup of Canadian small-caps of between $100-million and $2.5-billion in market capitalization making news and on the move today.

Aurora Cannabis Inc. (ACB-T) says it's buying H2 Biopharma Inc., based in Lachute, Que. for $25-million. It said the price will be "satisfied through the issuance of Aurora common shares."

Aurora said it will make an initial payment of $10-million and further payments based on performance-related milestones, including completion of a cannabis-production facility the company is building.

Story continues below advertisement

"The latest Aurora acquisition will be the company's fourth production facility in Canada - and second site in Quebec, in addition to its 40,000-square-foot production "Aurora Vie" facility in Pointe-Claire, on the island of Montreal," the company stated.

In a separate release, Aurora said it has formally commenced its offer to buy CanniMed Therapeutics Inc. (CMED-T) for $24 per share. A condition of the offer is that Aurora's takeover of Newstrike Resources Inc. (HIP-X) be terminated.

**

Semafo Inc. (SMF-T) says board chairman Jean Lamarre passed away on Wednesday following a short illness. Mr. Lamarre joined the board in 1997 and was appointed chairman in 2000.

**

Scientific Games Corp. (SGMS-Q) has increased its stake in  NYX Gaming Group Ltd. (NYX-X) to more than 36 per cent from 10.7 per cent through various share transactions.

**

Story continues below advertisement

Valener Inc. (VNR-T) reported a loss of $2.2-million in the fourth quarter compared to a loss of $800,000 a year earlier.

The loss was 7 cents per share compared to 2 cents a year earlier. Analysts were expecting a loss of 11 cents per share in the latest quarter.

**

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter